AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Equitable Trust Co.

Equitable Trust Co. cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.6% during the third quarter, HoldingsChannel reports. The fund owned 56,986 shares of the company’s stock after selling 950 shares during the period. Equitable Trust Co.’s holdings in AstraZeneca were worth $4,440,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in AZN. Martin Investment Management LLC lifted its stake in shares of AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC boosted its stake in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares during the period. Creative Planning increased its position in shares of AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares during the last quarter. TD Asset Management Inc raised its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock valued at $104,160,000 after acquiring an additional 121,876 shares during the period. Finally, Northcape Wealth Management LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at approximately $269,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 0.3 %

AZN opened at $64.49 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The stock has a market capitalization of $199.96 billion, a price-to-earnings ratio of 31.15, a PEG ratio of 1.18 and a beta of 0.47. The business has a fifty day moving average price of $77.53 and a 200 day moving average price of $78.55. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.